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Inverse alterations in plasma levels of low-density lipopro­
tein cholesterol and high-density lipoprotein cholesterol are 
recognized side effects of systemic treatment with the syn­
thetic retinoids isotretinoin and etretinate. 
The mass quotients of total plasma cholesterol and high­
density lipoprotein cholesterol as well as low-density lip­
oprotein cholesterol and high-density lipoprotein choles­
terol are well-established predictive risk factors of car­
diovascular disease. We evaluated and compared these 
lipoprotein cholesterol ratios of80 patients treated system­
ically with isotretinoin (13-cis-retinoic acid) and 81 patients 
treated with etretinate (aromatic retinoid). 
Lipoprotein cholesterol data were derived from 5 lipid 
studies on isotretinoin, including our own results, and 4 
published lipid studies on etretinate. For all isotretinoin 
and etretinate lipid studies, significant increases in the mean 
plasma levels of total cholesterol and low-density lipopro-
H 
yperlipidemias are important risk factors of coro­
nary heart disease, one of the major causes of death 
in the United States and other industrialized coun­
tries. Unfortunately, the synthetic retinoids, iso­
tretinoin (13-cis-retinoic acid; Accutane in the U. S.A., 
Roaccutan in Europe) and etretinate (aromatic retinoid; Tegison 
in the U.S.A., Tigason in Europe) as well as pharmacologic doses 
of vitamin A (retinol) induce secondary hyperlipoproteinemias, 
involving disturbances of plasma triglyceride and cholesterol me­
tabolism [1-3]. Until recently, hypertriglyceridemia has been dis­
cussed as the major lipid side effect of systemic retinoid therapy. 
However, with regard to epidemiologic considerations, retinoid­
induced disturbances of lipoprotein cholesterol metabolism might 
contribute to a more critical increase in incidence of coronary 
heart disease, as retinoids are frequently used for the treatment 
of common and widespread dermatologic diseases, like nodulo-
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tein cholesterol and significant decreases in the mean con­
centration of high-density lipoprotein cholesterol were 
demonstrated. 
In comparison with etretinate, oral isotretinoin gave rise 
to a nearly twofold percent increase of both lipoprotein 
cholesterol ratios from pretreatment levels. Furthermore, 
for isotretinoin, an approximately linear dose-related in­
crease of the ratio of low-density lipoprotein cholesterol 
and high-density lipoprotein cholesterol could be observed. 
If sustained over long periods, the mean differential rise 
of the ratio of low-density lipoprotein cholesterol and high­
density lipoprotein cholesterol of 0.92 ± 0.51 for isotre­
tinoin and 0.56 ± 0.10 for etretinate indicates an increased 
risk of cardiovascular disease for both retinoids. Etretinate 
could be identified as the less harmful retinoid for pro­
longed oral therapy. ] Invest Dermatol 88:395-435, 1987 
cystic acne, rosacea, disorders of keratinization, severe psoriasis, 
as well as skin cancer prevention [4,5]. This concern is supported 
by epidemiologic correlations between serum retinol levels and 
the concentrations of total cholesterol, as well as low-density 
lipoprotein cholesterol, that have been reported from the Evans 
County Cardiovascular Disease Cohort Study [6] and the New 
Zealand Study [7]. 
Based on various epidemiologic and clinical studies, the quo­
tients of total cholesterol and high-density lipoprotein (HDL)­
cholesterol as well as low-density lipoprotein (LDL)-cholesterol 
and HDL-cholesterol have been shown to be important diagnostic 
parameters, capable of differentiating between individuals with 
and without coronary heart disease [8-13]. Although several lipid 
studies on synthetic retinoids included determinations of plasma 
levels of LDL-cholesterol and HDL-cholesterol, only little atten­
tion has been paid to the resulting lipoprotein cholesterol ratios 
and their epidemiologic significance for the prediction of risk for 
coronary heart disease. 
Figure 1 illustrates the pathophysiologic role of the quotient of 
atherogenic LDL-cholesterol [14] and antiatherogenic HDL-cho­
lesterol [15] for the assessment of the efficacy of the reverse cho­
lesterol transport and its role in the pathogenesis of atherosclerosis 
[16-18]. 
The purpose of this study is the evaluation of the atherogenic 
risk of retinoid-induced disturbances of plasma cholesterol me­
tabolism by comparison of lipoprotein cholesterol ratios during 
systemic retinoid therapy with equivalent lipoprotein cholesterol 
ratios of well accepted epidemiologic studies on prevalence, in­
cidence, and predictive risk of cardiovascular disease [8,11-13]. 
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Figure 1. Conceptual overview of lipoprotein cholesterol homeostasis. 
During hyperlipidemic states, cholesteryl ester-rich LDL accumulate in 
macrophages. so-called scavenger cells. which convert to foam cells, the 
cellular substrate of atheromatous arterial lesions. The reverse cholesterol 
transport to the liver probably depends on HDL receptor-mediated reen­
docytosis of HDL [17]. Reendocytosed cholesteryl ester-enriched HDLE 
are taken up by hepatocytes via the apo E-receptor [18]. LPL = lipo­
protein lipase, LCAT = lecithin-cholesterol acyltransferase. Apo E = 
apoprotein E. 
MATERIALS AND METHOD S 
Assembly of Isotretinoin and Etretinate Patient Cohorts 
Statistically significant total serum cholesterol and lipoprotein 
cholesterol values of 5 lipid studies on isotretinoin, performed by 
Lyons et al [19], van der Schroeffet al [20], Vahlquist et al [21], 
and Zech et al [22], as well as our own study on 20 patients, were 
evaluated before and during systemic isotretinoin treatment. These 
studies were compared with 4 lipid studies on etretinate, published 
by Ellis et al [23], Gollnick et al [24], Michaelsson et al [25], and 
V ahlquist et al [21]. The resulting isotretinoin cohort is composed 
of 80 patients (60 men, 20 women) with a mean age of 30.1 ± 
2.8 years who received a mean daily dose of 0.62 ± 0.06 mg 
isotretinoin per kilogram body weight. 
The etretinate cohort consists of81 patients (43 men, 38 women) 
with a mean age of 49.8 ± 8.0 years who received a mean daily 
dose of 0.87 ± 0.14 mg etretinate per kilogram body weight. 
In all studies, triglycerides, total cholesterol, and HDL-cho­
lesterol were determined. With the exception of 3 lipid studies 
[19,20,23] LDL-cholesterol was measured in each study. For these 
3 studies serum levels of LD L-cholesterol could be reliably cal­
culated from the values of total triglyceride, total cholesterol, and 
HDL-cholesterol using the Friedewald formula [26]. 
Isotretinoin Lipid Study We determined total cholesterol, 
HDL-cholesterol, LDL-cholesterol, the quotients of total choles­
terol and HDL-cholesterol, as well as LDL-cholesterol and HDL­
cholesterol of 20 patients with severe acne (13 men, 7 women; 
mean age 25.3 years) who received a mean daily dose of 0.70 mg 
isotretinoin per kilogram body weight. None of these patients 
revealed overweight, unusual dietary habits, received other med­
ications during the course of isotretinoin treatment, or had a 
history of preexisting lipid disorder or other metabolic diseases. 
Lipid and lipoprotein values were obtained before the first dose 
of isotretinoin was administered and subsequently at two-week 
intervals. Pretreatment values and values at maximal expression 
of hyperlipidemia, determined by the peak of the serum triglyc­
eride concentration (8th week of treatment) were compared. Each 
subject acted as his or her own control. 
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Lipid Analyses Blood for cholesterol and lipoprotein choles­
terol determinations was drawn following a 14-h overnight fast. 
Serum cholesterol was determined by the enzymatic CHOD -P AP 
method (Monotest Cholesterol, Boehringer Mannheim, F.R.G.). 
High-density lipoprotein cholesterol was determined after prior 
precipitation of apoprotein B-containing lipoprotein fractions with 
magnesium phosphotungstate reagent (Boehringer Mannheim). 
The level of LDL-cholesterol was measured after selective pre­
cipitation with polyvinylsulfate (Boehringer Mannheim). 
Statistics Significances of differences between lipid values be­
fore and during isotretinoin treatment were calculated by the 
Student's I-test for paired data. 
RESULTS 
Isotretinoin Lipid Study Lipoprotein cholesterol values and 
lipoprotein cholesterol ratios of 13 male and 7 female patients are 
presented in Tables I and II. The mean serum cholesterol level 
increased by 5.6% from mean pretreatment levels in men, and 
8.4% in women. Simultaneously, LDL-cholesterol increased by 
2.7% in men, and 16.0% in women. An inverse relationship 
between LDL-cholesterol and HDL-cholesterol, which decreased 
by 11.0% in men, and 24.4% in women, could be observed, 
whereas total cholesterol levels remained within the normal range 
for the patients' ages. None of the patients had total cholesterol 
levels exceeding 260 mg/ dl during isotretinoin treatment. 
With regard to lipoprotein cholesterol ratios, more obvious 
changes became apparent. The quotient of total cholesterol and 
HDL-cholesterol increased by 18.9% in men and 43.9% in women. 
Concomitantly, the ratio of LDL-cholesterol and HDL-choles­
terol revealed a marked elevation in men and women of 15.2% 
and 54.0%, respectively. 
Effect of Isotretinoin and Etretinate on Cholesterol Ratios 
Figure 2, upper panel, shows the mean ratios ofLDL-cholesterol 
and HDL-cholesterol derived from 4 published lipid studies [19-22] 
and our own study. Each study revealed a marked mean increase 
of the cholesterol ratio resulting in an average rise of 30. 1 % from 
pretreatment values for all 5 studies. 
Figure 2, lower panel, demonstrates the mean ratios of LDL­
cholesterol and HDL-cholesterol of 4 lipid studies on etretinate 
[21,23-25]. For each study a less marked elevation of the mean 
cholesterol ratios could be demonstrated with an average increase 
of 16.2%. 
Correlation Between Retinoid Dose and Cholesterol Ratio 
To elucidate the relationship between the daily isotretinoin dose 
and the percent increase of the ratio ofLDL-cholesterol and HDL­
cholesterol, means of 8 lipid studies [2,19-22,27,28, and our own 
study], with a dose range of 0.05-2.0 mg isotretinoin per kilo­
gram body weight were analyzed. Our own study of 20 patients 
(mean daily dose of 0.70 mg/kg body weight) resulted in a mean 
Table I. Total Serum Cholesterol and Lipoprotein 
Cholesterol Before Isotretinoin Treatment and D uring 
Maximal Expression of Hyperlipidemia (8th week) 
Total 
Subjects Cholesterol LDL-cholesterol HDL-cholesterol 
Before Rx 
0, /I = 13 178.6 ± 41.4 112.2 ± 38.0 43.7 ± 8.0 
�, /I = 7 192.1 ± 52.9 119.0 ± 55.0 55.8 ± 22.3 
During Rx 
0, /I = 13 188.6 ± 31.6 115. 2 ± 34.5 38.9 ± 8.1 
�, /I = 7 208.4 ± 47.8 138.1 ± 47.4 42.1 ± 9.5 
Significance of p < 0.143 P < 0.360 P < 0.011 
differences, 
/I = 20 
Results shown are mean ± SD (mg/dl). 
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Table II. Lipoprotein Cholesterol Ratios Before Isotretinoin 
Treatment and D uring Maximal Expression of Hyperlipidemia 
(8th week) 
Total Cholesterol LDL-cholesterol 
Subjects HDL-cholesterol HDL-cholesterol 
Before Rx 
ci,n = 13 4. 08 ± 1.07 2. 57 ± 1.00 
�, n = 7 3. 44 ± 1. 67 2. 13 ± 1. 54 
During Rx 
ci, n = 13 4. 85 ± 0. 90 2. 96 ± 0. 67 
�, n = 7· 4. 95 ± 1. 00 3. 28 ± 1.10 
Significance of p < 0.001 P < 0.066 
differences, 
n = 20 
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Figure 2. Increase of LDL-cholesteroIlHDL-cholesterol quotients during 
systemic treatment with isotretinoin (top) and etretinate (bottom). Each 
line represents the mean cholesterol quotient of one lipid study on iso­
tretinoin [19-22] and etretinate [21,23-25]. The lowest line in the upper 
panel represents our study. Age- and sex-corrected normal means of the 
ratio of LDL-cholesterol and HDL-cholesterol are indicated by the dotted 
horizontal lines. 
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Figure 3. Correlation between isotretinoin dose and percentage increase 
of the quotient of LDL-cholesterol and HDL-cholesterol. Each solid circle 
represents the mean of the cholesterol ratios of one isotretinoin lipid study 
[2,19-22, 27, 28, our own study]. 
increase of the ratio of LDL-cholesterol and HDL-cholesterol of 
25.0% from pretreatment levels. An approximately linear cor­
relation (r = 0.58) between the daily isotretinoin dose and the 
increase of the ratio of LDL-cholesterol and HDL-cholesterol is 
demonstrable (Fig 3). 
For etretinate, dose-dependent elevations of the cholesterol ra­
tio could not be identified. 
Estimation of Atherogenic Risk The Framingham Offspring 
Study [8] revealed a significant correlation between the quotient 
of total cholesterol and HDL-cholesterol and the prevalence of 
coronary heart disease. As illustrated in Fig 4, an increase of this 
quotient is highly correlated with an increase in prevalence of 
coronary heart disease. When long-term isotretinoin- and etre­
tinate-induced mean changes of the cholesterol ratio are com­
pared, a retinoid-induced increase in prevalence of coronary heart 
disease must be expected. 
Figure 5 shows the comparison of the quotients of LDL-cho­
lesterol and HDL-cholesterol of 179 coronary angiography pa­
tients [9] with cholesterol quotients of the isotretinoin and etre-
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Figure 4. Estimation of prevalence of coronary heart disease after long­
term retinoid treatment. The plot represents the Framingham study [8]. 
The superimposed horizontal arrows illustrate the retinoid-induced mean 
alterations of the cholesterol quotients, the dotted extensions the corre­
sponding standard deviations. Data are derived from 5 studies on isotre­
tinoin [19-22, our own study], and 4 studies on etretinate [21,23-25]. 
The dotted curve shows the relative frequency of individuals without 
coronary heart disease (CHD), the solid curve the relative frequency of 
patients with CHD. 
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Figure 5. Comparison of LD L-cholesterol/HDL-cholesterol quotients of 
179 coronary angiography patients [9] with patients before and during 
systemic treatment with isotretinoin and etretinate. Means and standard 
deviations of cholesterol ratios are calculated from previous work [19-22, 
our own study] as well as others [21,23-25]. C = patients with normal 
coronary angiogram, I = patients with single-vessel disease, <50% ste­
nosis, II = patients with single-vessel disease, >50% stenosis, III = 
patients with multiple-vessel disease. 
tinate patient cohorts. Both retinoids lead to mean elevations of 
the cholesterol quotienf exceeding those values observed in pa­
tients with single-vessel coronary heart disease, having a stenosis 
of one coronary artery of less than 50%. 
According to the Lipid Research Clinics Primary Prevention 
Trial [13], a cholesterol-lowering regimen of dietary restriction 
and cholestyramine treatment in hypercholesterolemic men re­
sulted in a decreased incidence of coronary artery disease. The 
data suggest for every 1 % reduction in the levels of plasma total 
cholesterol and LDL-cholesterol a 1-2% reduction of risk for 
coronary artery disease. In quantitative terms, a decrement of 
22.3 mg/ dl in LD L-cholesterol levels was associated with a 16-19% 
reduction in risk for coronary heart disease. 
The mean differential increments in LDL-cholesterol of 19.9 
± 6.8 mg/dl caused by isotretinoin treatment (data derived from 
the isotretinoin cohort) and 13.1 ± 7.2 mg/dl during etretinate 
therapy (data derived from the etretinate cohort), if maintained 
over prolonged periods, may contribute to an increased risk for 
coronary heart disease. 
Furthermore, the Lipid Research Clinics [13] point to an im­
portant, independent role for HDL in the risk equation. The mean 
differential decrements of HDL-cholesterol levels of 5.6 ± 3.8 
mg/dl in isotretinoin-treated patients (data derived from the iso­
tretinoin cohort) and 3.7 ± 1.6 mg/ dl in etretinate-treated patients 
(data derived from the etretinate cohort) have to be viewed with 
senous concern. 
Thus, the mean differential rise of the LDL-cholesterol/HD L­
cholesterol ratio of 0.92 ± 0.51 for the isotretinoin cohort and 
0.56 ± 0.10 for the etretinate cohort are the result of an increase 
of atherogenic LDL-cholesterol and a concomitant decrease of 
protective HDL-cholesterol. 
DISCUSSION 
Administration of oral vitamin A and the synthetic retinoids, 
isotretinoin and etretinate, to humans and experimental animals 
results in changes of serum lipid metabolism [2,3]. The most 
apparent side effect on lipid metabolism is that of hypertrigly­
ceridemia due to increased serum triglycerides in the very-low­
density lipoprotein (VLDL) fraction [1,29-31]. Little attention 
has been paid to retinoid-induced alterations of lipoprotein cho­
lesterol metabolism [21,22,32]. 
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Our understanding of the role of cholesterol and its lipoprotein 
carriers in the development of coronary heart disease has been 
advanced by several metabolic and epidemiologic studies that 
have been recently reviewed by the Atherosclerosis Study Group 
[12]. Attention has been focused particularly on the atherogenic 
potential of the various lipoprotein-cholesterol fractions [11]. El­
evations of the quotients of LDL-cholesterol and HDL-choles­
terol, as well as total serum cholesterol and HDL-cholesterol are 
associated with increased risk for cardiovascular disease [8-13]. 
All lipid studies on isotretinoin and etretinate consistently revealed 
significant increases ofLDL-cholesterol and decrements of HDL­
cholesterol levels. D uring isotretinoin treatment, the mean ratio 
of total cholesterol and HDL-cholesterol rose from 4.47 ± 0.25 
to 5.79 ± 0.90, during systemic etretinate therapy from 5.09 ± 
0.67 to 5.96 ± 0.78. A total cholesterollHDL-cholesterol ratio 
of 5.0 indicates an average high risk for cardiovascular disease. 
A ratio above 4.5 is cause for concern, whereas optimal ratios are 
in the vicinity of 3.5 [12]. The higher pretreatment levels of this 
ratio observed in the etretinate cohort might be explained by the 
higher mean age of 49.8 ± 8.0 years compared with 30.1 ± 2.8 
years of the isotretinoin cohort. Retinoid-induced disturbances of 
lipoprotein metabolism are especially disadvantageous in higher 
age groups. 
Our findings from 20 isotretinoin-treated patients are in good 
agreement with a recent study [32] of 60 patients treated daily 
with 1 mg isotretinoin per kilogram body weight for severe no­
dulocystic acne. Significant elevations in mean LDL-cholesterol 
levels of 19 mg/ dl in men and 15 mg/ dl in women, and significant 
decreases in mean HDL-cholesterol of 6.9 mg/dl in men and 5.6 
mg/dl in women have been observed. The mean ratios of LDL­
cholesterol and HDL-cholesterol in both men and women in­
creased from relatively safe levels of 2.4 and 2. 3 to borderline 
levels of 3.0. 
Retinoid-induced elevations of the LDL-cholesterollHDL-cho­
lesterol ratio are due to an increase of atherogenic LDL-cholesterol 
and a simultaneous decrease of antiatherogenic HDL-cholesterol. 
The atherogenic effect of LDL is well studied in patients with 
familial hypercholesterolemia. It has been postulated that LDL at 
high levels accumulate in the arterial wall where they are taken 
up by scavenger celis, including mononuclear macro phages (Fig 
1). The uptake of LDL-cholesterol induces foam cell formation 
and thereby accelerates atherosclerosis [14]. 
The antiatherogenic role of HDL, which physiologically trans­
ports 25% of total serum cholesterol, has been proven in nu­
merous epidemiologic and clinical studies [8,15,33]. The protec­
tive effect of HDL-cholesterol is at least as strong as the disease­
promoting effect of LDL-cholesterol and is independent of other 
lipid risk factors [11]. Every 10 mg/dl difference in HDL-cho­
lesterol is associated with a 50% difference in risk of coronary 
heart disease [12]. It is generally accepted that HDL promote 
cholesterol effiux from macrophages [16]. Further support is de­
rived from Schmitz et al [17] who demonstrated a specific binding 
site for HDL on macrophages. In the presence of HDL, choles­
terol-laden macrophages release unesterified cholesterol via a spe­
cific receptor-mediated reendocytosis mechanism. Cholesterol­
and apoprotein E-enriched HDL (HDLE) are reendo�ytosed into 
the plasma compartment, thereby probably transporting HDLE-
cholesterol to the liver via the hepatic apoprotein E-receptor [18] 
(Fig 1). 
The serum total cholesterol level is maintained by a two-way 
traffic of peripheral cholesterol influx and effiux, with the net 
effect best reflected by the LDL-cholesterol/HDL-cholesterol ra­
tio or the highly correlated total cholesterollHDL-cholesterol ra­
tio [12]. 
In conclusion, retinoid-induced side effects on lipoprotein cho­
lesterol metabolism must be considered potentially serious, as 
they increase the concentration of atherogenic LDL-cholesterol 
and simultaneously impair counterregulatory protective mecha­
nisms of reverse cholesterol transport. 
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